Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.
A value-based deal would boost prices should Astrazeneca's struggling heart-disease pill Brilinta outperform outcomes benchmarks.
Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
The failure of the Stellar-4 study of selonsertib is a big blow for Gilead, but has not dented enthusiasm for other Nash players.
Intercept Pharmaceuticals and the whole Nash field await Ocaliva’s pivotal readout.
Tiny signs of a therapeutic benefit are offset by safety worries, as the company pivots to higher doses and second-generation projects.
The acquisition marked Astrazeneca’s formal embrace of biologicals. Today the Medimmune name was dropped.
Results of the prostate cancer project’s pivotal Aramis trial, already known to be positive, are presented for the first time.
Johnson & Johnson’s $3.4bn move for the robotic surgery specialist Auris Health could be bad news for its Verb Surgical joint venture.
Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.
Others in the FDA queue include Bausch’s psoriasis therapy Duobrii and Motif Bio’s antibiotic Iclaprim.
Despite missing pretty much all the endpoints of a registrational study, the Danish company insists that it has a chance of approval for a treatment for an incurable…